S&P 500   3,435.56 (-0.22%)
DOW   28,210.82 (-0.35%)
QQQ   284.19 (-0.08%)
AAPL   116.87 (-0.54%)
MSFT   214.80 (+0.07%)
FB   278.73 (+4.17%)
GOOGL   1,585.99 (+2.25%)
AMZN   3,184.94 (-1.00%)
TSLA   422.64 (+0.17%)
NVDA   540.99 (-0.88%)
BABA   307.97 (-0.59%)
CGC   19.49 (+3.23%)
GE   7.32 (-0.27%)
MU   53.31 (-0.41%)
AMD   79.20 (-2.89%)
T   26.72 (-0.15%)
F   7.85 (+1.42%)
ACB   4.85 (+6.36%)
GILD   60.21 (-0.56%)
NFLX   489.05 (-6.92%)
BA   163.86 (-2.02%)
BAC   24.05 (-0.37%)
NIO   27.86 (-0.36%)
S&P 500   3,435.56 (-0.22%)
DOW   28,210.82 (-0.35%)
QQQ   284.19 (-0.08%)
AAPL   116.87 (-0.54%)
MSFT   214.80 (+0.07%)
FB   278.73 (+4.17%)
GOOGL   1,585.99 (+2.25%)
AMZN   3,184.94 (-1.00%)
TSLA   422.64 (+0.17%)
NVDA   540.99 (-0.88%)
BABA   307.97 (-0.59%)
CGC   19.49 (+3.23%)
GE   7.32 (-0.27%)
MU   53.31 (-0.41%)
AMD   79.20 (-2.89%)
T   26.72 (-0.15%)
F   7.85 (+1.42%)
ACB   4.85 (+6.36%)
GILD   60.21 (-0.56%)
NFLX   489.05 (-6.92%)
BA   163.86 (-2.02%)
BAC   24.05 (-0.37%)
NIO   27.86 (-0.36%)
S&P 500   3,435.56 (-0.22%)
DOW   28,210.82 (-0.35%)
QQQ   284.19 (-0.08%)
AAPL   116.87 (-0.54%)
MSFT   214.80 (+0.07%)
FB   278.73 (+4.17%)
GOOGL   1,585.99 (+2.25%)
AMZN   3,184.94 (-1.00%)
TSLA   422.64 (+0.17%)
NVDA   540.99 (-0.88%)
BABA   307.97 (-0.59%)
CGC   19.49 (+3.23%)
GE   7.32 (-0.27%)
MU   53.31 (-0.41%)
AMD   79.20 (-2.89%)
T   26.72 (-0.15%)
F   7.85 (+1.42%)
ACB   4.85 (+6.36%)
GILD   60.21 (-0.56%)
NFLX   489.05 (-6.92%)
BA   163.86 (-2.02%)
BAC   24.05 (-0.37%)
NIO   27.86 (-0.36%)
S&P 500   3,435.56 (-0.22%)
DOW   28,210.82 (-0.35%)
QQQ   284.19 (-0.08%)
AAPL   116.87 (-0.54%)
MSFT   214.80 (+0.07%)
FB   278.73 (+4.17%)
GOOGL   1,585.99 (+2.25%)
AMZN   3,184.94 (-1.00%)
TSLA   422.64 (+0.17%)
NVDA   540.99 (-0.88%)
BABA   307.97 (-0.59%)
CGC   19.49 (+3.23%)
GE   7.32 (-0.27%)
MU   53.31 (-0.41%)
AMD   79.20 (-2.89%)
T   26.72 (-0.15%)
F   7.85 (+1.42%)
ACB   4.85 (+6.36%)
GILD   60.21 (-0.56%)
NFLX   489.05 (-6.92%)
BA   163.86 (-2.02%)
BAC   24.05 (-0.37%)
NIO   27.86 (-0.36%)
Log in
NASDAQ:GMDA

Gamida Cell Stock Forecast, Price & News

$5.42
-0.36 (-6.23 %)
(As of 10/21/2020 12:00 AM ET)
Add
Compare
Today's Range
$5.30
Now: $5.42▼
$5.75
50-Day Range
$4.07
MA: $4.50▼
$5.80
52-Week Range
$2.60
Now: $5.42▼
$7.70
Volume399,736 shs
Average Volume203,680 shs
Market Capitalization$131.28 million
P/E RatioN/A
Dividend YieldN/A
Beta1.89
Gamida Cell Ltd., a clinical stage biopharmaceutical company, focuses on developing cell therapies to cure cancer, and rare and serious hematologic diseases. The company's lead product candidate is NiCord, a nicotinamide (NAM)-expanded cord blood cell therapy that is in Phase III studies in patients with high-risk hematologic malignancies, as well as in Phase I/II studies in patients with severe aplastic anemia. It is also developing NAM-NK, an innate immunotherapy, which is in Phase I studies for the treatment of relapsed or refractory non-Hodgkin lymphoma and multiple myeloma. The company was founded in 1998 and is headquartered in Jerusalem, Israel.
Read More

Beat the Market (BTM) Rank™

Analyst Opinion: 3.5Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank™

1.57 out of 5 stars

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:GMDA
Previous Symbol
CUSIPN/A
CIKN/A
Webwww.gamida-cell.com
Phone972-2659-5666
Employees79

Debt

Debt-to-Equity RatioN/A
Current Ratio6.69
Quick Ratio6.69

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / Cash FlowN/A
Book Value$1.44 per share
Price / Book3.76

Profitability

EPS (Most Recent Fiscal Year)($1.69)
Net Income$-34,350,000.00
Net MarginsN/A
Return on Equity-109.47%
Return on Assets-63.13%

Miscellaneous

Outstanding Shares24,222,000
Market Cap$131.28 million
Next Earnings Date11/11/2020 (Estimated)
OptionableNot Optionable
$5.42
-0.36 (-6.23 %)
(As of 10/21/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive GMDA News and Ratings via Email

Sign-up to receive the latest news and ratings for GMDA and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Gamida Cell (NASDAQ:GMDA) Frequently Asked Questions

How has Gamida Cell's stock price been impacted by COVID-19 (Coronavirus)?

Gamida Cell's stock was trading at $4.23 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, GMDA stock has increased by 28.1% and is now trading at $5.42.
View which stocks have been most impacted by COVID-19.

Do Wall Street analysts recommend investors buy shares of Gamida Cell?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Gamida Cell in the last year. There are currently 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Gamida Cell.

When is Gamida Cell's next earnings date?

Gamida Cell is scheduled to release its next quarterly earnings announcement on Wednesday, November 11th 2020.
View our earnings forecast for Gamida Cell.

How were Gamida Cell's earnings last quarter?

Gamida Cell Ltd (NASDAQ:GMDA) posted its earnings results on Tuesday, August, 11th. The company reported ($0.37) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.26) by $0.11.
View Gamida Cell's earnings history.

What price target have analysts set for GMDA?

6 brokerages have issued 1 year price objectives for Gamida Cell's stock. Their forecasts range from $13.00 to $20.00. On average, they anticipate Gamida Cell's share price to reach $16.40 in the next year. This suggests a possible upside of 202.6% from the stock's current price.
View analysts' price targets for Gamida Cell.

Are investors shorting Gamida Cell?

Gamida Cell saw a drop in short interest during the month of September. As of September 30th, there was short interest totaling 198,100 shares, a drop of 18.2% from the September 15th total of 242,100 shares. Based on an average daily volume of 219,300 shares, the days-to-cover ratio is presently 0.9 days. Currently, 0.7% of the shares of the stock are short sold.
View Gamida Cell's Short Interest.

Who are some of Gamida Cell's key competitors?

Some companies that are related to Gamida Cell include Autolus Therapeutics (AUTL), Aptose Biosciences (APTO), MeiraGTx (MGTX), Proteon Therapeutics (PRTO), BiondVax Pharmaceuticals (BVXV), Orchard Therapeutics (ORTX), Rubius Therapeutics (RUBY), Sutro Biopharma (STRO), Voyager Therapeutics (VYGR), Aerie Pharmaceuticals (AERI), Freeline Therapeutics (FRLN), Scholar Rock (SRRK), Harpoon Therapeutics (HARP), Surface Oncology (SURF) and Cellular Biomedicine Group (CBMG).
View all competitors.

What other stocks do shareholders of Gamida Cell own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Gamida Cell investors own include Matinas BioPharma (MTNB), BioNano Genomics (BNGO), Gran Tierra Energy (GTE), ADMA Biologics (ADMA), Pennsylvania Real Estate Investment Trust (PEI), Zosano Pharma (ZSAN), Cannabics Pharmaceuticals (CNBX), KushCo (KSHB), Enerplus (ERF) and Novan (NOVN).

Who are Gamida Cell's key executives?

Gamida Cell's management team includes the following people:
  • Dr. Julian Adams Ph.D., CEO & Director (Age 65, Pay $740k)
  • Mr. Shai Lankry CPA, M.B.A., Chief Financial Officer (Age 44, Pay $353k)
  • Dr. Ronit Simantov, Chief Medical Officer (Age 55, Pay $587k)
  • Mr. Joshua D. Hamermesh MBA, Chief Bus. Officer (Age 48, Pay $508k)
  • Mr. Thomas J. Klima, Chief Commercial Officer (Age 48, Pay $392k)

When did Gamida Cell IPO?

(GMDA) raised $50 million in an initial public offering on Friday, October 26th 2018. The company issued 3,600,000 shares at a price of $13.00-$15.00 per share. BMO Capital Markets and RBC Capital Markets served as the underwriters for the IPO and Needham & Company Oppenheimer & Co. was co-manager.

What is Gamida Cell's stock symbol?

Gamida Cell trades on the NASDAQ under the ticker symbol "GMDA."

Who are Gamida Cell's major shareholders?

Gamida Cell's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Wedbush Securities Inc. (0.07%) and Vigilare Wealth Management (0.05%).

Which major investors are buying Gamida Cell stock?

GMDA stock was purchased by a variety of institutional investors in the last quarter, including Wedbush Securities Inc., and Vigilare Wealth Management.

How do I buy shares of Gamida Cell?

Shares of GMDA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Gamida Cell's stock price today?

One share of GMDA stock can currently be purchased for approximately $5.42.

How big of a company is Gamida Cell?

Gamida Cell has a market capitalization of $131.28 million. The company earns $-34,350,000.00 in net income (profit) each year or ($1.69) on an earnings per share basis. Gamida Cell employs 79 workers across the globe.

What is Gamida Cell's official website?

The official website for Gamida Cell is www.gamida-cell.com.

How can I contact Gamida Cell?

Gamida Cell's mailing address is 5 NAHUM HAFZADI STREET GIVAAT SHAUL, JERUSALEM L3, 91340. The company can be reached via phone at 972-2659-5666 or via email at [email protected]

This page was last updated on 10/21/2020 by MarketBeat.com Staff
Receive Analysts' Upgrades and Downgrades Daily

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.